Sanjivani Paranteral Ltd Stock Price Today (NSE: SANJIVIN)
Fundamental Score
Sanjivani Paranteral Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Sanjivani Paranteral Ltd share price today is ₹132.75, down 4.83% on NSE/BSE as of 30 March 2026. Sanjivani Paranteral Ltd (SANJIVIN) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹238.99 (Cr). The 52-week high for SANJIVIN share price is ₹268.80 and the 52-week low is ₹137.95. At a P/E ratio of 32.04x, SANJIVIN is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 24.58% and a debt-to-equity ratio of 0.15.
Sanjivani Paranteral Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Sanjivani Paranteral Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Sanjivani Paranteral Share Price: A Financial Stability Analysis
The pharmaceutical industry, often considered recession-resistant, faces constant pressure from evolving regulations and the need for continuous R&D investment. This analysis evaluates the financial stability of Sanjivani Paranteral Ltd, focusing on its current financials and comparing it to its sector peers. The current Sanjivani Paranteral share price stands at ₹197.0500030517578, with a Price-to-Earnings (PE) ratio of 32.04 and a Return on Capital Employed (ROCE) of 30.21%. These metrics offer initial insights into the company's valuation and profitability.
A crucial factor in assessing financial stability is profitability. Sanjivani Paranteral's ROCE of 30.21% suggests efficient capital utilization. This high ROCE can contribute to a stronger economic moat, allowing the company to reinvest profits at attractive rates and maintain a competitive advantage. Sustained high ROCE figures often indicate a company's ability to generate higher returns compared to its cost of capital, leading to increased shareholder value. However, it's vital to assess the consistency and drivers behind this ROCE to determine its sustainability.
Comparing Sanjivani Paranteral to its peers provides a broader perspective. For example,
Mankind Pharma Ltd, a more established player, likely benefits from economies of scale and a wider product portfolio. A critical aspect often discussed among investors is management quality, where perceptions of Mankind Pharma Ltd might be different due to its longer track record and corporate governance practices. While not directly quantifiable, management quality plays a significant role in navigating the complexities of the pharmaceutical sector and ultimately impacting long-term performance. Similarly, comparing against companies like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd regarding their capital structures and debt levels is important.This analysis is part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra. The data presented is observational and intended for informational purposes only. It does not constitute financial advice or a recommendation to buy or sell securities. Further due diligence is recommended before making any investment decisions related to Sanjivani Paranteral Ltd.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sanjivani Paranteral Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SANJIVIN across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Return on Equity (24.58%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (30.21%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Consistent Growth Track Record (33.89% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (34.19% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (46.45% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.15)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (15.64x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Profit Decline Concern (-28.70%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-14.51%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Negative Free Cash Flow (₹-13.86 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 6.02%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Sanjivani Paranteral Ltd Financial Statements
Comprehensive financial data for Sanjivani Paranteral Ltd including income statement, balance sheet and cash flow
About SANJIVIN (Sanjivani Paranteral Ltd)
Sanjivani Paranteral Ltd is a dynamic pharmaceutical manufacturer rooted in India, dedicated to crafting essential medicines that address a broad spectrum of health needs. The comp...any's core competency lies in the production of high-quality pharmaceutical formulations, delivered through a diverse range of administration routes. These include meticulously crafted oral solid dosages, guaranteeing ease of use and consistent therapeutic effects, alongside precision-engineered small volume parenterals, enabling rapid and targeted drug delivery. Furthermore, Sanjivani Paranteral specializes in sterile powder formulations, ensuring the integrity and efficacy of sensitive medications. The commitment to quality and innovation permeates every stage of their manufacturing process. Sanjivani Paranteral's therapeutic focus extends across a multitude of critical healthcare domains. The company provides medications for central nervous system disorders, contributing to the management of neurological conditions and mental well-being. They also produce treatments for cardiovascular ailments, aiding in the prevention and control of heart-related diseases. Their antibiotic range combats bacterial infections, while their gastroenterological products support digestive health. Addressing the growing prevalence of diabetes, Sanjivani Paranteral offers anti-diabetic medications, and they also supply anti-allergic formulations to alleviate allergic reactions. This comprehensive approach reflects the company’s dedication to meeting the diverse healthcare demands of the population. Beyond its core product lines, Sanjivani Paranteral demonstrates a commitment to diversifying its offerings and adapting to evolving patient needs. The company manufactures soft gelatin capsules, including those packed with multivitamins, providing a convenient way to supplement dietary deficiencies and promote overall wellness. In the topical arena, they formulate corticosteroids, antiseptics, nonsteroidal anti-inflammatory drugs (NSAIDs), and anti-bacterial creams and ointments, addressing a wide array of skin conditions and infections. Their range also extends to nasal sprays, providing targeted relief for nasal congestion and allergies. This broad portfolio underscores Sanjivani Paranteral's dedication to providing comprehensive healthcare solutions.
Company Details
Key Leadership
Corporate Events
Latest News
SANJIVIN Share Price: Frequently Asked Questions
What is the current share price of Sanjivani Paranteral Ltd (SANJIVIN)?
As of 30 Mar 2026, 12:06 pm IST, Sanjivani Paranteral Ltd share price is ₹132.75. The SANJIVIN stock has a market capitalisation of ₹238.99 (Cr) on NSE/BSE.
Is SANJIVIN share price Overvalued or Undervalued?
SANJIVIN share price is currently trading at a P/E ratio of 32.04x, compared to the industry average of 31.77x. Based on this relative valuation, the Sanjivani Paranteral Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of SANJIVIN share price?
The 52-week high of SANJIVIN share price is ₹268.80 and the 52-week low is ₹137.95. These values are updated daily from NSE/BSE price data.
What factors affect the Sanjivani Paranteral Ltd share price?
Key factors influencing SANJIVIN share price include quarterly earnings growth (Sales Growth: -14.51%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Sanjivani Paranteral Ltd a good stock for long-term investment?
Sanjivani Paranteral Ltd shows a 5-year Profit Growth of 46.45% and an ROE of 24.58%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.15 before investing in SANJIVIN shares.
How does Sanjivani Paranteral Ltd compare with its industry peers?
Sanjivani Paranteral Ltd competes with major peers in the Pharmaceuticals. Investors should compare SANJIVIN share price P/E of 32.04x and ROE of 24.58% against the industry averages to determine competitive standing.
What is the P/E ratio of SANJIVIN and what does it mean?
SANJIVIN share price has a P/E ratio of 32.04x compared to the industry average of 31.77x. Investors pay ₹32 for every ₹1 of annual earnings.
How is SANJIVIN performing according to Bull Run's analysis?
SANJIVIN has a Bull Run fundamental score of 44.4/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SANJIVIN belong to?
SANJIVIN operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Sanjivani Paranteral Ltd share price.
What is Return on Equity (ROE) and why is it important for SANJIVIN?
SANJIVIN has an ROE of 24.58%, which indicates excellent management efficiency. ROE measures how efficiently Sanjivani Paranteral Ltd generates profits from shareholders capital.
How is SANJIVIN debt-to-equity ratio and what does it indicate?
SANJIVIN has a debt-to-equity ratio of 0.15, which indicates conservative financing with low financial risk.
What is SANJIVIN dividend yield and is it a good dividend stock?
SANJIVIN offers a dividend yield of 0.26%, meaning you receive ₹0.26 annual dividend for every ₹100 invested in Sanjivani Paranteral Ltd shares.
How has SANJIVIN share price grown over the past 5 years?
SANJIVIN has achieved 5-year growth rates of: Sales Growth 33.89%, Profit Growth 46.45%, and EPS Growth 34.19%.
What is the promoter holding in SANJIVIN and why does it matter?
Promoters hold 31.20% of SANJIVIN shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Sanjivani Paranteral Ltd.
What is SANJIVIN market capitalisation category?
SANJIVIN has a market capitalisation of ₹239 crores, placing it in the Small-cap category.
How volatile is SANJIVIN stock?
SANJIVIN has a beta of N/A. A beta > 1 suggests the Sanjivani Paranteral Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SANJIVIN operating profit margin trend?
SANJIVIN has a 5-year average Operating Profit Margin (OPM) of 14.49%, indicating the company's operational efficiency.
How is SANJIVIN quarterly performance?
Recent quarterly performance shows Sanjivani Paranteral Ltd YoY Sales Growth of -14.51% and YoY Profit Growth of -28.70%.
What is the institutional holding pattern in SANJIVIN?
SANJIVIN has FII holding of 0.00% and DII holding of 6.02%. Significant institutional holding often suggests professional confidence in the Sanjivani Paranteral Ltd stock.